The Board of Directors of the Society of Infectious Diseases Pharmacists (SIDP) is pleased to announce the availability of funding for an Infectious Diseases Pharmacotherapy Residency for the period of July 2022 through June 2023. The intent of this funding is to foster the development and/or expansion of new advanced training opportunities for pharmacists committed to the practice area of infectious diseases pharmacotherapy. Applications will only be considered from programs developing a new infectious diseases specialty training program in 2022 or established programs expanding the number of available infectious diseases resident positions.

SIDP will provide funding to support the resident salary for one year plus fringe benefits and will include $1,500 travel support to attend the SIDP live Business Meeting at IDWeek™ (total grant not to exceed $75,000). The program will be responsible for any additional funding required to support resident salary plus fringe benefits.

SIDP members who have received an SIDP Residency Grant award as Residency Director in the past, institutions who have received an SIDP Residency or Fellowship Grant award in the past three years, and current members of the SIDP Board of Directors are ineligible for these awards.

Members who are awarded funding must send a copy of the letter of acceptance from the resident plus CV and proof of PGY1 residency training to SIDP Headquarters no later than May 1, 2022 or the award will be rescinded. A midpoint and final report of the resident’s activities (e.g. rotations including stewardship activities, key presentations, longitudinal research) will be also required.

Completed applications should be electronically submitted as follows:

Applications should be entered online at the SIDP website (www.sidp.org) using the resident award application form. The RPD cover letter, two (2) letters of support, and curriculum vitas (up to 4) should be converted to a single PDF file and uploaded. Other information will be directly inserted on the web form. Questions regarding submission may be submitted to the SIDP Secretary, Warren Rose (warren.rose@wisc.edu). Proposals must be submitted no later than 5 PM E.D.T. on October 8, 2021. Applications submitted after this deadline will not be considered. The Board of Directors will make decisions on the applications no later than October 22, 2021.

For residencies, applicants are encouraged to refer to the ASHP Educational Outcomes, Goals, and Objectives for Postgraduate Year Two (PGY2) Pharmacy Residencies in Infectious Diseases. These guidelines were prepared by ASHP in collaboration with ACCP and SIDP and endorsed by the SIDP Board of Directors. SIDP supports the utility of the ASHP Educational Outcomes, Goals, and Objectives for PGY2 Pharmacy Residencies in Infectious Diseases for any residency funded by SIDP.
Criteria for Award Evaluation

Residency Program Director/Primary Preceptor
1. Is an Active member of SIDP at the time of application and not currently serving on the Board of Directors.
2. Has completed advanced training in ID pharmacotherapy (PGY2 residency or fellowship) or has at least 3 years of experience as an active clinical practitioner or researcher in ID pharmacotherapy.
3. Has experience in precepting or directing postgraduate training.
4. Demonstrates commitment to further development of the ID residency with ongoing institutional support after SIDP funding period.
5. RPD and preceptor qualifications evaluated include clinical service, precepting experience, scholarship, and service to the profession

Institution:
1. Is capable of providing a full range of training experiences which may include inpatient care, outpatient care, antimicrobial stewardship, pediatrics, HIV, microbiology laboratory, infection control, and a longitudinal experience. Antimicrobial stewardship need not be the focus of a program, but it should be an important element.
2. Has administrative support of the residency training program as indicated in an accompanying letter of support. The administrative support should indicate commitment to a plan for a sustainable, institution-supported ID residency following SIDP funding year.
3. Has adequate space and resources identified to support resident training.
4. Has existing infrastructure to support a specialty training program.
5. Has not received an SIDP Residency or Fellowship Grant award in the past 3 years.
6. Institutional environment factors including pharmacy practice model, multidisciplinary collaboration including infectious diseases or other key stakeholder physicians, patient populations served

Residency Candidate:
1. Possesses a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy.
2. Has completed a PGY1 Residency, is currently in training in a PGY1 residency program that will be completed before the start of this program or has equivalent pharmacy practice experience.

Residency Program:
1. Follows the guidance of the ASHP Accreditation Standard for PGY2 Pharmacy Residency Programs. Available at: https://www.ashp.org/Professional-Development/Residency-Information/Residency-Program-Resources.
2. Program characteristics including clinical rotation experiences, opportunities in teaching, research, service, trainee’s role in antimicrobial stewardship program

Required Elements for Application
1. A letter of application from individual who will serve as residency director. The letter should include the following components: rationale for development of a new program or expansion of a new position, preceptor and institution qualifications, and program goals. The letter should be limited to a 2 page maximum.
2. A letter of support from Director of Pharmacy Services or administrative equivalent at the primary facility where residency training will occur. This letter of support should also include administrative commitment to a plan for ID residency support following SIDP funding year.
3. A letter of support from a key stakeholder physician (e.g. Chief of Infectious Diseases or antimicrobial stewardship physician) who will work with the resident during the training program.
4. A current curriculum vitae for the program director and for up to three additional individuals who will serve as preceptors during the training experience.
5. A description of the institution where primary training will occur. It is recommended to include a description of the following: pharmacy department structure; pharmacy practice model; infectious diseases services infrastructure; service lines/patient population. Responses should be limited to 500 words or less.

6. A description of resident opportunities in teaching/academics, research and professional/community service. Responses should be limited to 750 words or less.

7. A description of rotation experiences. Responses should be limited to 500 words or less